Search results
Results from the WOW.Com Content Network
Aspirin is ≈170-fold more potent in inhibiting COX-1 than COX-2. [40] Studies of meloxicam 7.5 mg per day for 23 days find a level of gastric injury similar to that of a placebo, and for meloxicam 15 mg per day a level of injury lower than that of other NSAIDs; however, in clinical practice meloxicam can still cause some ulcer complications.
[1] [11] Celecoxib and parecoxib have a sulfonamide substituent (SO 2 NH 2) in para-position on one of the aryl rings while etoricoxib and rofecoxib have a methylsulfone (SO 2 CH 3). [12] The oxidation state on the sulfur is important for selectivity; sulfones and sulfonamides are selective for COX-2 but sulfoxides and sulfides are not. The ...
Etoricoxib, sold under the brand name Arcoxia, is a selective COX-2 inhibitor developed and commercialized by Merck.It is approved in 63 countries worldwide as of 2007, except the United States where the Food and Drug Administration sent a Non Approvable Letter to Merck and required them to provide additional data.
Acute use (1–3 days) yields a potency about 1.5× stronger than that of morphine and chronic use (7 days+) yields a potency about 2.5 to 5× that of morphine. Similarly, the effect of tramadol increases after consecutive dosing due to the accumulation of its active metabolite and an increase of the oral bioavailability in chronic use.
An analgesic drug, also called simply an analgesic, antalgic, pain reliever, or painkiller, is any member of the group of drugs used for pain management.Analgesics are conceptually distinct from anesthetics, which temporarily reduce, and in some instances eliminate, sensation, although analgesia and anesthesia are neurophysiologically overlapping and thus various drugs have both analgesic and ...
Non-steroidal anti-inflammatory drugs [1] [3] (NSAID) [1] are members of a therapeutic drug class which reduces pain, [4] decreases inflammation, decreases fever, [1] and prevents blood clots. Side effects depend on the specific drug, its dose and duration of use, but largely include an increased risk of gastrointestinal ulcers and bleeds ...
The therapeutic recommended dosages were 12.5, 25, and 50 mg with an approximate bioavailability of 93%. [12] [13] [14] Rofecoxib crossed the placenta and blood–brain barrier, [12] [13] [15] and took 1–3 hours to reach peak plasma concentration with an effective half-life (based on steady-state levels) around 17 hours.
Loxoprofen is a nonsteroidal anti-inflammatory drug (NSAID) in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is available in some countries for oral administration. A transdermal preparation was approved for sale in Japan in January 2006; [1] medicated tape and gel formulations followed in ...